Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with limited therapeutic options beyond surgery and cytotoxic chemotherapy. The success of immune checkpoint inhibition has been found to correlate with expression of immune-related genes such as CD274 (PD-L1) in lung and other...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 684025
Main Authors Wadowski, Benjamin, Bueno, Raphael, De Rienzo, Assunta
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 11.06.2021
Subjects
checkpoint
genomics
immune
mesothelioma
microenvironment
Oncology
transcriptomics
Online AccessGet full text
ISSN2234-943X
2234-943X
DOI10.3389/fonc.2021.684025

Cover

More Information
Summary:Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with limited therapeutic options beyond surgery and cytotoxic chemotherapy. The success of immune checkpoint inhibition has been found to correlate with expression of immune-related genes such as CD274 (PD-L1) in lung and other solid cancers. However, only a small subset of MPM patients respond to checkpoint inhibition, and this response has been varied and unpredictable across several clinical trials. Recent advances in next-generation sequencing (NGS) technology have improved our understanding of the molecular features of MPM, also with respect to its genetic signature and how this impacts the immune microenvironment. This article will review current evidence surrounding the interplay between MPM genetics, including epigenetics and transcriptomics, and the immune response.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Emanuela Felley-Bosco, University of Zurich, Switzerland
Reviewed by: Fonteneau Jean-Francois, U1232 Centre de Recherche en Cancérologie et Immunologie Nantes Angers (CRCINA) (INSERM), France; Didier Jean, Institut National de la Santé et de la Recherche Médicale (INSERM), France
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2021.684025